CCL2 and neoplasm: In the early stages, SASP components such as IL-6, IL-8, and CCL2 recruit immune cells to eliminate damaged cells, but prolonged SASP signaling alters this equilibrium, driving chronic inflammation, suppression of immune responses, and ECM remodeling, thereby facilitating tumor development [67].